CD46 and gastric cancer: For instance, negative regulators of complement (such as CD46, CD55, and CD59) have been found to be highly expressed in gastric cancers (55–57), which could potentially explain why T+P therapies failed to offer a significant clinical benefit in the JACOB Phase III trials of gastric HER2+ cancers (58).